Clene Inc Ordinary Shares CLNN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLNN is a good fit for your portfolio.
News
-
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
-
IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington
-
Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®
-
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
-
Clene to Present at the 36th Annual ROTH Conference
-
Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024
-
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Trading Information
- Previous Close Price
- $0.34
- Day Range
- $0.34–0.35
- 52-Week Range
- $0.25–1.09
- Bid/Ask
- $0.34 / $0.35
- Market Cap
- $45.17 Mil
- Volume/Avg
- 148,177 / 932,158
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 56.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 85
- Website
- https://www.clene.com
Comparables
Valuation
|
Metric
|
CLNN
|
CRNX
|
PNT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 11.36 |
Price/Book Value | 3.37 | 5.56 | 3.12 |
Price/Sales | 56.43 | 636.71 | 5.50 |
Price/Cash Flow | — | — | 13.90 |
Price/Earnings
CLNN
CRNX
PNT
Financial Strength
|
Metric
|
CLNN
|
CRNX
|
PNT
|
|---|---|---|---|
Quick Ratio | 1.43 | 12.92 | 9.01 |
Current Ratio | 1.53 | 13.07 | 9.14 |
Interest Coverage | −10.17 | — | — |
Quick Ratio
CLNN
CRNX
PNT
Profitability
|
Metric
|
CLNN
|
CRNX
|
PNT
|
|---|---|---|---|
Return on Assets (Normalized) | −92.82% | −38.81% | 20.67% |
Return on Equity (Normalized) | −424.53% | −44.79% | 23.56% |
Return on Invested Capital (Normalized) | −105.63% | −45.62% | 23.38% |
Return on Assets
CLNN
CRNX
PNT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cldrsssnwz | Fmhp | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Szkhvxc | Szphpcc | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wkjcfjb | Gqrwtzj | $97.3 Bil | |
MRNA
| Moderna Inc | Ptmfcvwt | Cjv | $41.3 Bil | |
ARGX
| argenx SE ADR | Xsjvxbkt | Dhvv | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fghvfqqz | Ntqg | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zwdgtkys | Ghhclm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ylwbjpyc | Hnsxn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zrnzvjkk | Rzvrz | $12.6 Bil | |
INCY
| Incyte Corp | Nldmzfgj | Pkrnm | $11.6 Bil |